ALPN - ニバリス・セラピュ―ティクス （Alpine Immune Sciences Inc.）ALPNのニュース
Eledon Pharmaceuticals Appoints Jan Hillson, M.D., to its Board of Directors 2021/07/02 12:00:00 Intrado Digital Media
IRVINE, Calif., July 02, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (Eledon) (NASDAQ: ELDN), a clinical stage biopharmaceutical company focused on developing targeted medicines for persons living with autoimmune disease, requiring an organ or cell-based transplant, or living with amyotrophic lateral sclerosis (ALS), today announced the appointment of Jan Hillson, M.D., to the companys Board of Directors. Dr. Hillson currently serves as Senior Vice President of Clinical Development at Alpine Immune Sciences, a clinical stage biopharmaceutical company dedicated to discovering and developing innovative, protein-based immunotherapies targeting the immune synapse to treat cancer and autoimmune and inflammatory diseases.
Alpine Immune Sciences Set to Join Russell 3000® Index 2021/06/08 00:00:00 BioSpace
Alpine Immune Sciences, Inc. announced Alpine is set to join the broad-market Russell 3000® Index at the conclusion of the 2021 Russell indexes annual reconstitution, effective after the US market opens on June 28, 2021, according to a preliminary list of additions posted by FTSE Russell on June 4, 2021.
Oppenheimer Maintains a Buy Rating on Alpine Immune Sciences (ALPN) 2021/06/07 03:35:18 Smarter Analyst
Oppenheimer analyst Mark Breidenbach maintained a Buy rating on Alpine Immune Sciences (ALPN) yesterday and set a price target of $19.00. The post Oppenheimer Maintains a Buy Rating on Alpine Immune Sciences (ALPN) appeared first on Smarter Analyst .
Alpine Immune Sciences'' Autoimmune Disease Candidate ALPN-303 Shows Promise in Preclinical Studies 2021/06/03 12:14:52 Benzinga
Alpine Immune Sciences Inc (NASDAQ: ALPN ) has presented the preclinical data from its ALPN-303 program at the European Alliance of Associations for Rheumatology (EULAR) European Congress of Rheumatology Virtual Meeting. ALPN-303 inhibited the activity of the B cell cytokines APRIL and BAFF more potently than wild-type TACI-Fc Full story available on Benzinga.com
H.C. Wainwright Remains a Buy on Alpine Immune Sciences (ALPN) 2021/06/03 10:25:23 Smarter Analyst
In a report released today, Joseph Pantginis from H.C. The post H.C. Wainwright Remains a Buy on Alpine Immune Sciences (ALPN) appeared first on Smarter Analyst .
Eledon Pharmaceuticals Appoints Jan Hillson, M.D., to its Board of Directors 2021/07/02 12:00:00 Intrado Digital Media
IRVINE, Calif., July 02, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (Eledon) (NASDAQ: ELDN), a clinical stage biopharmaceutical company focused on developing targeted medicines for persons living with autoimmune disease, requiring an organ or cell-based transplant, or living with amyotrophic lateral sclerosis (ALS), today announced the appointment of Jan Hillson, M.D., to the companys Board of Directors. Dr. Hillson currently serves as Senior Vice President of Clinical Development at Alpine Immune Sciences, a clinical stage biopharmaceutical company dedicated to discovering and developing innovative, protein-based immunotherapies targeting the immune synapse to treat cancer and autoimmune and inflammatory diseases.
Alpine Immune Sciences Set to Join Russell 3000® Index 2021/06/08 00:00:00 BioSpace
Alpine Immune Sciences, Inc. announced Alpine is set to join the broad-market Russell 3000® Index at the conclusion of the 2021 Russell indexes annual reconstitution, effective after the US market opens on June 28, 2021, according to a preliminary list of additions posted by FTSE Russell on June 4, 2021.
Oppenheimer Maintains a Buy Rating on Alpine Immune Sciences (ALPN) 2021/06/07 03:35:18 Smarter Analyst
Oppenheimer analyst Mark Breidenbach maintained a Buy rating on Alpine Immune Sciences (ALPN) yesterday and set a price target of $19.00. The post Oppenheimer Maintains a Buy Rating on Alpine Immune Sciences (ALPN) appeared first on Smarter Analyst .
Alpine Immune Sciences'' Autoimmune Disease Candidate ALPN-303 Shows Promise in Preclinical Studies 2021/06/03 12:14:52 Benzinga
Alpine Immune Sciences Inc (NASDAQ: ALPN ) has presented the preclinical data from its ALPN-303 program at the European Alliance of Associations for Rheumatology (EULAR) European Congress of Rheumatology Virtual Meeting. ALPN-303 inhibited the activity of the B cell cytokines APRIL and BAFF more potently than wild-type TACI-Fc Full story available on Benzinga.com
H.C. Wainwright Remains a Buy on Alpine Immune Sciences (ALPN) 2021/06/03 10:25:23 Smarter Analyst
In a report released today, Joseph Pantginis from H.C. The post H.C. Wainwright Remains a Buy on Alpine Immune Sciences (ALPN) appeared first on Smarter Analyst .
Alpine Immune Sciences Set to Join Russell 3000® Index 2021/06/08 00:00:00 BioSpace
Alpine Immune Sciences, Inc. announced Alpine is set to join the broad-market Russell 3000® Index at the conclusion of the 2021 Russell indexes annual reconstitution, effective after the US market opens on June 28, 2021, according to a preliminary list of additions posted by FTSE Russell on June 4, 2021.
Oppenheimer Maintains a Buy Rating on Alpine Immune Sciences (ALPN) 2021/06/07 03:35:18 Smarter Analyst
Oppenheimer analyst Mark Breidenbach maintained a Buy rating on Alpine Immune Sciences (ALPN) yesterday and set a price target of $19.00. The post Oppenheimer Maintains a Buy Rating on Alpine Immune Sciences (ALPN) appeared first on Smarter Analyst .
Alpine Immune Sciences'' Autoimmune Disease Candidate ALPN-303 Shows Promise in Preclinical Studies 2021/06/03 12:14:52 Benzinga
Alpine Immune Sciences Inc (NASDAQ: ALPN ) has presented the preclinical data from its ALPN-303 program at the European Alliance of Associations for Rheumatology (EULAR) European Congress of Rheumatology Virtual Meeting. ALPN-303 inhibited the activity of the B cell cytokines APRIL and BAFF more potently than wild-type TACI-Fc Full story available on Benzinga.com